Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
Recruiting · NCT05873712 · Registry updated 2026-03-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome | Recurrent Transformed B-Cell Non-Hodgkin Lymphoma; Recurrent Transformed Chronic Lymphocytic Leukemia; Recurrent Transformed Non-Hodgkin Lymphoma; Refractory Transformed; Refractory Transformed B-cell Non-Hodgkin Lymphoma; Refractory Transformed Chronic Lymphocytic Leukemia; Refractory Transformed Non-Hodgkin Lymphoma; Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma | Recruiting | Phase 2 | 2026-03-03 | NCT05873712 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Aseel Alsouqi | 1 |
| BeOne Medicines | 76 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Huntsman Cancer Institute | Salt Lake City | United States | 107 |
| Icahn School of Medicine at Mount Sinai | New York | United States | 342 |
| Ohio State University Comprehensive Cancer Center | Columbus | United States | 548 |